PMID- 11369052
OWN - NLM
STAT- MEDLINE
DCOM- 20010906
LR  - 20190816
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 125
IP  - 2
DP  - 2001 Mar
TI  - Dedifferentiation of a well-differentiated liposarcoma to a highly malignant 
      metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 
      1q22-q24 associated with metastases.
PG  - 100-11
AB  - Well-differentiated liposarcomas (WDLPS), especially those located in the 
      retroperitoneum, may occasionally undergo dedifferentiation. Although this 
      process is associated with a more aggressive clinical course, dedifferentiated 
      liposarcomas rarely produces metastases. The case reported here is rather 
      uncommon: A retroperitoneal WDLPS gave lung metastases that were diagnosed as 
      highly malignant osteosarcomas. We used comparative genomic hybridization (CGH), 
      fluorescence in situ hybridization (FISH), and Southern blot analyses to 
      characterize the copy number changes and genetic aberrations occurring at 
      different stages of the disease. In the primary tumor, the only detectable 
      aberration was amplification of 12q13-q14, which was present only in a fraction 
      of the cells and revealed by FISH analysis. High-level amplification of 
      12q13-q14, involving CDK4, MDM2, and HMGIC, was seen both in the relapse and the 
      metastases. The second most common change, gain or high-level amplification of 
      1q22-q24, was detectable by CGH only in the osteogenic metastases, as was loss of 
      the distal 2q. FISH analyses revealed considerable heterogeneity in the samples, 
      and the percentage of cells showing aberrations was significantly higher in the 
      metastatic samples. In particular, increased copy numbers of 789f2, a marker for 
      1q21 amplification in sarcomas, was observed in more than 65% of the cells in the 
      metastatic samples, but in less than 10% of the cells from the recurrent samples. 
      These observations could indicate that 1q amplification, in particular, may be 
      indicative of a more malignant phenotype and ability of metastasis in WDLPS, as 
      has also been suggested by others.
FAU - Forus, A
AU  - Forus A
AD  - Department of Tumor Biology, The Norwegian Radium Hospital, 0301, Oslo, Norway. 
      anne.forus@labmed.uio.no
FAU - Larramendy, M L
AU  - Larramendy ML
FAU - Meza-Zepeda, L A
AU  - Meza-Zepeda LA
FAU - Bjerkehagen, B
AU  - Bjerkehagen B
FAU - Godager, L H
AU  - Godager LH
FAU - Dahlberg, A B
AU  - Dahlberg AB
FAU - Saeter, G
AU  - Saeter G
FAU - Knuutila, S
AU  - Knuutila S
FAU - Myklebost, O
AU  - Myklebost O
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Adult
MH  - Blotting, Northern
MH  - Blotting, Southern
MH  - Cell Differentiation/genetics
MH  - Centromere/ultrastructure
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 1/genetics/*ultrastructure
MH  - Chromosomes, Human, Pair 12/genetics/*ultrastructure
MH  - Combined Modality Therapy
MH  - Fatal Outcome
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Liposarcoma/genetics/*pathology/therapy
MH  - Lung Neoplasms/genetics/pathology/*secondary
MH  - Neoplasm Metastasis/*genetics
MH  - Neoplasm Recurrence, Local/genetics/*pathology
MH  - Oncogenes
MH  - Osteosarcoma/genetics/pathology/*secondary
MH  - Retroperitoneal Neoplasms/genetics/*pathology/therapy
EDAT- 2001/05/23 10:00
MHDA- 2001/09/08 10:01
CRDT- 2001/05/23 10:00
PHST- 2001/05/23 10:00 [pubmed]
PHST- 2001/09/08 10:01 [medline]
PHST- 2001/05/23 10:00 [entrez]
AID - S0165-4608(00)00369-1 [pii]
AID - 10.1016/s0165-4608(00)00369-1 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2001 Mar;125(2):100-11. doi: 
      10.1016/s0165-4608(00)00369-1.